HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Imperiali, M. Articles by Oxenius, A. Search for Related Content PubMed PubMed Citation Articles by Imperiali, M. Articles by Oxenius, A. Agricola Articles by Imperiali, M. Articles by Oxenius, A.

Post-translational modification of -dystroglycan is not critical for lymphocytic choriomeningitis virus receptor function in vivo

Mauro Imperiali^1,

¹ Institute for Microbiology, ETH Zurich, 8093 Zürich, Switzerland
² Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK

Correspondence
Annette Oxenius
oxenius{at}micro.biol.ethz.ch

-Dystroglycan (-DG) is a ubiquitously expressed molecule that has been identified as a cellular receptor for lymphocytic choriomeningitis virus (LCMV) and other arenaviruses. Recently, it was demonstrated that LCMV receptor function is critically dependent on post-translational modifications, namely glycosylation. In particular, it was shown that O-mannosylation, a rare type of mammalian O-linked glycosylation, is important in determining the binding of LCMV to its cellular receptor. All studies carried out so far showed a dependence on glycosylation in LCMV receptor function in vitro. This work extended these studies to two in vivo models of -DG hypoglycosylation. The results confirm earlier findings on the in vitro dependence of carbohydrate modifications in LCMV receptor function. However, experiments in animal models showed that this dependence was only very weak in vivo. It is likely that alternative receptors or alternative entry pathways may account for this attenuated in vivo phenotype.

Present address: Ospedale San Giovanni, Laboratorio di Chimica Clinica, 6500 Bellinzona, Switzerland.